@article{article, title  = {{The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model.}},

 url = {{}},

 year = {{2013}},

 month = {{4}},

 author = {{Hoyle M and Crathorne L and Peters J and Jones-Hughes T and Cooper C and Napier M and Tappenden P and Hyde C}},

 doi = {{10.3310/hta17140}},

 volume = {{17}},

 journal = {{Health Technol Assess}},

 issue = {{14}},

 pages = {{1-237}},

 note = {{Accessed on 2025/01/13}}}